GWS
REGN icon

Greykasell Wealth Strategies’s Regeneron Pharmaceuticals REGN Stock Holding History

Greykasell Wealth Strategies’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$369K Hold
478
– – 0.15% 106
2025
Q4 		$369K Buy
478
+113
+31% +$76.7K 0.15% 107
2025
Q3 		$205K Sell
365
-34
-9% -$19.2K 0.09% 136
2025
Q2 		$209K Sell
399
-309
-44% -$172K 0.1% 129
2025
Q1 		$449K Hold
708
– – 0.24% 86
2024
Q4 		$504K Buy
+708
New +$594K 0.28% 84

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Greykasell Wealth Strategies's REGN Position: Q1 2026 in Review

Greykasell Wealth Strategies held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 478 shares worth $369K. The position accounts for 0.15% of the portfolio, ranked #106.

Greykasell Wealth Strategies first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $504K in Q4 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Greykasell Wealth Strategies held 478 shares of Regeneron Pharmaceuticals worth $369K as of Q1 2026.
  • Greykasell Wealth Strategies left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.15% of Greykasell Wealth Strategies's portfolio in Q1 2026, its #106 holding.
  • Greykasell Wealth Strategies first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Greykasell Wealth Strategies's Regeneron Pharmaceuticals position peaked at $504K in Q4 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q1 2026, filed 7 May 2026.